Clarus Ventures has raised $660 million for its second life sciences fund. Principals with the fund say they've invested 90 percent of the first biotech fund of $500 million, which was raised in 2005. And the life sciences field has remained hot for investors. The National Venture Capital Association, PricewaterhouseCoopers and Thomson Financial concluded that a third of all venture money went to biotech and medical device makers in the last quarter of 2007.
"We have effectively completed the deployment of our first fund and built a diversified portfolio of exciting companies," said Robert Liptak, a Clarus Ventures Managing Director. "These include companies with...breakthrough products and technologies such as Aerovance, Centaurus, CoMentis, ESBATech, Pearl, ProActa, SarCode, Taligen, and Variation."
- read the release for more
- check out the report from The Boston Globe
Clarus closes $500M fund. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report
The top 20 VC deals of 2007. Report
Biotech, emerging markets are big VC targets. Report